Advertisement

International Journal of Clinical Pharmacy

, Volume 38, Issue 4, pp 863–869 | Cite as

Prescribing patterns of non-steroidal anti-inflammatory drugs in chronic kidney disease patients in the South African private sector

  • Willem P. Meuwesen
  • Jesslee M. du PlessisEmail author
  • Johanita R. Burger
  • Martie S. Lubbe
  • Marike Cockeran
Research Article

Abstract

Background Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used pharmaceutical agents worldwide. NSAIDs are considered nephrotoxic and should therefore be used with caution or be avoided completely in high risk patients, such as chronic kidney disease (CKD) patients. Objective This study aimed to investigate the prescribing of NSAIDs in CKD patients in order to generate awareness and improve the outcome of these patients. Setting The study was conducted using medicine claims data in the private health sector of South Africa. Method A descriptive, quantitative study was performed, using retrospective data obtained from a Pharmaceutical Benefit Management company. Data from 1 January 2009 to 31 December 2013 were analysed. The study population consisted of all patients with an ICD-10 code for a CKD (N18), in association with a paid claim for an NSAID. Main outcome measure The stratification of NSAID prescribing volume among the CKD population in terms of gender, age, NSAID type, dosage and prescriber type. Results The prescribing of NSAIDs in CKD patients varied between 26 and 40 % over the 5 year study period. No association between gender and CKD patients who received NSAIDs versus those who did not was found, with p > 0.05 and Cramer’s V < 0.1 for each year of the study. The association between age groups and CKD patients who received NSAIDs versus those who did not was statistically significant, but practically weak (p < 0.05; Cramer’s V ≥ 0.1). Most NSAID prescriptions (52–63 %) were for patients aged 35–64 years. Diclofenac (34.25 %) was the single most frequently prescribed NSAID, but the COX-2-inhibitors (celecoxib, meloxicam and etoricoxib) were the preferred NSAID class to be prescribed. The majority (61.6 %) of the NSAIDs were prescribed by general medical practitioners in dosages meeting and even exceeding the recommended daily dosage of patients with normal kidney function. Conclusions Even though NSAIDs are regarded as nephrotoxic drugs, they are still being prescribed to at-risk CKD patients, in particular, the elderly.

Keywords

Chronic kidney disease Non-steroidal anti-inflammatory drugs  NSAIDs Private health sector South Africa 

Notes

Acknowledgments

Thanks should be given to Ms Anne-Marie Bekker, as she contributed with administrative support regarding the database. We also acknowledge the North-West University (Potchefstroom Campus) and the National Research Foundation (NRF) for their financial support.

Funding

None.

Conflicts of interest

We declare that we have no financial or personal relationship(s) which may have inappropriately influenced us in writing this paper.

References

  1. 1.
    Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol. 2006;25:S22–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Paul AD, Chauhan CK. Study of usage of nonsteroidal anti-inflammatory drugs (NSAIDs) among different practice categories in Indian clinical setting. Eur J Clin Pharmacol. 2005;60:889–92.CrossRefPubMedGoogle Scholar
  3. 3.
    Solomon DH, Furst DE, Romain PL. NSAIDs: Mechanism of action. 2015. http://www.uptodate.com/contents/nsaids-mechanism-of-action. Accessed 27 Jun 2014.
  4. 4.
    Tsai HJ, Hsu YH, Huang YW, Chang YK, Liu JS, Hsu CC. Use of non-steroidal anti-inflammatory drugs and risk of chronic kidney disease in people with type 2 diabetes mellitus, a nationwide longitudinal cohort study. Diabet Med. 2015;32:382–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30(3):247–55.CrossRefPubMedGoogle Scholar
  6. 6.
    Plantinga L, Grubbs V, Sarkar U. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Family Med. 2011;9(5):423–30.CrossRefGoogle Scholar
  7. 7.
  8. 8.
    Santoro D, Satta E, Messina S, Costantino G, Savica V, Bellinghieri G. Pain in end-stage renal disease: a frequent and neglected clinical problem. Clin Rheumatol. 2012;78(1):S2–11.Google Scholar
  9. 9.
    Cohen SD, Patel SS, Khetpal P, Peterson RA, Kimmel PL. Pain, sleep disturbance and quality of life in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:919–25.CrossRefPubMedGoogle Scholar
  10. 10.
    Kafkia T, Chamney M, Drinkwater A, Pegoraro M, Sedgewick J. Pain in chronic kidney disease: prevalence, cause and management. J Ren Care. 2011;37(2):114–22.CrossRefPubMedGoogle Scholar
  11. 11.
    Parmar MS, Parmar KS. Management of acute and post-operative pain in chronic kidney disease. 2013. http://www.readcube.com/articles/10.12688%2Ff1000research.2-28.v3. Accessed 29 Jun 2015.
  12. 12.
    Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009;4:1275–83.CrossRefPubMedGoogle Scholar
  13. 13.
    Ahmed Z, Simon B, Choudhury D. Management of diabetes in patients with chronic kidney disease. Postgrad Med. 2009;121(3):52–60.CrossRefPubMedGoogle Scholar
  14. 14.
    Loh AHL, Cohen AH. Drug-induced kidney disease–pathology and current concepts. Ann Acad Med. 2009;38:240–50.Google Scholar
  15. 15.
    Council for Medical Schemes, South Africa. Medical Schemes beneficiaries. 2015. http://indicators.hst.org.za/healthstats/159/data. Accessed 8 Aug 2015.
  16. 16.
    WHO (World Health Organization). International Statistical Classification of Diseases and Related Health Problems 10th Revision. http://apps.who.int/classifications/icd10/browse/2015/en#/VI. Accessed 8 Aug 2015.
  17. 17.
    MediKredit. National Pharmaceutical Product Index (NAPPI) Product Suite. 2014. https://www.medikredit.co.za/index.php?option=com_content&view=article&id=21&Itemid=31. Accessed 6 May 2014.
  18. 18.
    World Health Organization (WHO). Introduction to drug utilization research. 2003. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Drug%20utilization%20research.pdf. Accessed 26 May 2014.
  19. 19.
    Snyman, J.R., ed. 2015. Monthly Index of Medicine Specialities, 55th ed. Johannesburg: MPASA.Google Scholar
  20. 20.
    Rossiter D, editor. South African Medicine Formulary. 11th ed. Cape Town: Health and Medical; 2014.Google Scholar
  21. 21.
    Bhopal S, Chan J, Ellis O. Non-steroidal anti-inflammatory drugs prescribing in chronic kidney disease: an observational study. Prim Health Care Res Dev. 2010;11(3):280–4.CrossRefGoogle Scholar
  22. 22.
    Ingrasciotta Y, Sultana J, Giorgianni F. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS ONE. 2014;9(2):1–8.CrossRefGoogle Scholar
  23. 23.
    Gluhovschi GH, Gluhovschi A, Anastasiu D, Petrica L, Gluhocschi C, Velciov S. Chronic kidney disease and the involvement of estrogen hormones in its pathogenesis and progression. Rom J Intern Med. 2012;50(2):135–44.PubMedGoogle Scholar
  24. 24.
    Trifiró G, Sultana J, Giorgianni F, et al. Chronic kidney disease requiring healthcare services: a new approach to evaluate epidemiology of renal disease. 2014. http://www.hindawi.com/journals/bmri/2014/268362/. Access 6 Jun 2015.
  25. 25.
    Otero A, de Francisco ALM, Gayoso P, Garcίa F. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia. 2010;30(1):78–86.PubMedGoogle Scholar
  26. 26.
    Zhang Q, Koenig W, Raum E, Stegmaier C, Brenner H, Rothenbacher D. Epidemiology of chronic kidney disease: results from a population of older adults in Germany. Prev Med. 2009;48:122–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Tomson C, Bailey P. Management of chronic kidney disease. Medicine. 2011;39(7):407–13.CrossRefGoogle Scholar
  28. 28.
    Chou R, Helfand M, Peterson K, Dana T, Roberts C. Comparative effectiveness and safety of analgesics for osteoarthritis. 2006. http://www.effectivehealthcare.ahrq.gov/repFiles/AnalgesicsFinal.pdf. Accessed 17 Aug 2015.
  29. 29.
    Hörl WH. Non-steroidal anti-inflammatory drugs and the kidney. Pharmaceuticals. 2010;3:2291–321.CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Howse MLP, Bell GM. Drugs and toxins that damage the kidney. Medicine. 2007;35(7):399–403.CrossRefGoogle Scholar
  31. 31.
    Hunter LJ, Wood DM, Dargan PI. The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. Open Access Emerg Med. 2011;3:39–48.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int. 2010;107(37):647–56.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  • Willem P. Meuwesen
    • 1
  • Jesslee M. du Plessis
    • 1
    Email author
  • Johanita R. Burger
    • 1
  • Martie S. Lubbe
    • 1
  • Marike Cockeran
    • 1
  1. 1.Medicine Usage in South Africa, Faculty of Health SciencesNorth-West UniversityPotchefstroomSouth Africa

Personalised recommendations